artenimol has been researched along with Recrudescence in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 8 (25.81) | 29.6817 |
| 2010's | 18 (58.06) | 24.3611 |
| 2020's | 4 (12.90) | 2.80 |
| Authors | Studies |
|---|---|
| Abreha, T; Adam, I; Anstey, NM; Assefa, A; Awab, GR; Baird, JK; Barber, BE; Chu, CS; Commons, RJ; Dahal, P; Daher, A; Davis, TME; Dondorp, AM; Grigg, MJ; Guerin, PJ; Hien, TT; Humphreys, GS; Hwang, J; Karunajeewa, H; Laman, M; Lidia, K; Moore, BR; Mueller, I; Nosten, F; Pasaribu, AP; Pereira, DB; Phyo, AP; Poespoprodjo, JR; Price, RN; Sibley, CH; Simpson, JA; Stepniewska, K; Sutanto, I; Thriemer, K; Thwaites, G; White, NJ; William, T; Woodrow, CJ | 1 |
| Blessborn, D; Byakika-Kibwika, P; Lamorde, M; Ssenyonga, R; Tarning, J | 1 |
| Adhikari, B; Cobelens, F; Day, NPJ; Dhorda, M; Dondorp, AM; Henriques, G; Imwong, M; Mayxay, M; Mukaka, M; Newton, PN; Peerawaranun, P; Peto, TJ; Phommasone, K; Pongvongsa, T; Promnarate, C; Sirithiranont, P; van Leth, F; von Seidlein, L; White, NJ | 1 |
| Adhikari, B; Cheah, PY; Chotivanich, K; Cobelens, F; Davoeung, C; Day, NPJ; Dhorda, M; Dondorp, AM; Hanboonkunupakarn, B; Hien, TT; Imwong, M; Jittmala, P; Kajeechiwa, L; Landier, J; Lwin, KM; Mayxay, M; Mukaka, M; Newton, PN; Nguon, C; Nguyen, TN; Nosten, FH; Nosten, S; Parker, DM; Peerawaranun, P; Peto, TJ; Phommasone, K; Pongvongsa, T; Promnarate, C; Proux, S; Pukrittayakamee, S; Rekol, H; Thwaites, GE; Thwin, MM; Tripura, R; van Leth, F; von Seidlein, L; White, NJ; Wiladphaingern, J | 1 |
| Arsanok, M; Chann, S; Dysoley, L; Jongsakul, K; Kheang Heng, T; Kuntawunginn, W; Lin, JT; Lon, C; Manning, JE; Nou, S; Pichyangkul, S; Satharath, P; Saunders, DL; Sea, D; Smith, PL; Sok, S; Spring, MD; Sriwichai, S; Vanachayangkul, P; Waters, NC; Wojnarski, M | 1 |
| Chen, Y; Dai, Z; Han, L; Huang, RY; Liang, CL; Liu, H; Lu, C; Qiu, F; Yan, Y; Zhang, Q | 1 |
| Buyze, J; D'Alessandro, U; Hachizovu, S; Kabuya, JB; Kasongo, W; Mulenga, J; Mulenga, M; Mwakazanga, D; Nambozi, M; Van Geertruyden, JP | 1 |
| Anstey, NM; Douglas, NM; Kenangalem, E; Malloy, MJ; Patriani, D; Poespoprodjo, JR; Price, RN; Simpson, JA; Soenarto, Y; Sugiarto, P | 1 |
| Banda, RL; Fulakeza, JRM; Hodel, EM; Lipenga, TR; Nkhoma, SC; Terlouw, DJ | 1 |
| Bosco, A; Conrad, M; Kalyesubula, S; Kibuuka, A; Kigozi, R; Kyambadde, P; Mulebeke, R; Opigo, J; Rosenthal, PJ; Senzoga, J; Vinden, J; Wallender, E; Yeka, A | 1 |
| Bancone, G; Carrara, VI; Chu, CS; Imwong, M; Jeeyapant, A; Lee, SJ; Nosten, F; Paw, MK; Phyo, AP; Poe, NP; Proux, S; Raksapraidee, R; Sriprawat, K; Tarning, J; Thinraow, S; Turner, C; Watson, J; White, NJ; Wiladphaingern, J; Wilairisak, P; Win, HH; Yotyingaphiram, W | 1 |
| Beshir, KB; Bousema, T; Chilongola, J; Drakeley, CJ; Hallett, RL; Kaur, H; Mweresa, CK; Ndaro, A; Okell, L; Omar, SA; Sauerwein, RW; Sawa, P; Schallig, HD; Shekalaghe, SA; Sutherland, CJ | 1 |
| Bethell, D; Buathong, N; Chann, S; Chaorattanakawee, S; Chuor, CM; Gosi, P; Juliano, JJ; Kaewkungwal, J; Kuntawunginn, W; Lanteri, C; Lin, J; Lon, C; Manning, JE; Nou, S; Satharath, P; Saunders, D; Se, Y; Sea, D; So, M; Spring, M; Sriwichai, S; Tang, D; Tyner, SD; Vanachayangkul, P; Walsh, DS | 1 |
| Batty, KT; Gibbons, PL; Kirkpatrick, CM; Moore, BR; Patel, K | 1 |
| Arinaitwe, E; Bigira, V; Conrad, M; Dorsey, G; Kakuru, A; Kamya, MR; Muhindo, MK; Rosenthal, PJ; Tappero, JW; Wanzira, H | 1 |
| Lon, C; Saunders, DL; Vanachayangkul, P | 1 |
| Bassat, Q; Borrmann, S; Mulenga, M; Pfeil, J; Talisuna, A; Tozan, Y | 1 |
| Domergue, A; Duru, V; Khim, N; Kim, S; Menard, D; Witkowski, B | 1 |
| Afonso, M; Dimbu, PR; Ferreira, CM; Fortes, F; Garrett, DO; Halsey, ES; He, Y; Kelley, JS; Kiniffo, R; Macaia, AP; Mbounga, E; Patel, DS; Plucinski, MM; Quivinja, J; Ringwald, P; Samutondo, C; Talundzic, E; Udhayakumar, V | 1 |
| Davis, TM; Gomorrai, PS; Griffin, S; Ilett, KF; Karunajeewa, HA; Kotab, K; Lautu, D; Law, I; Lin, E; Mueller, I; Oa, O; Page-Sharp, M; Salman, S; Senn, M; Siba, P; Suano, P; Tarongka, N; Ura, A; Wong, R | 1 |
| An, SS; Ariey, F; Chotivanich, K; Das, D; Day, NP; Dondorp, AM; Hanpithakpong, W; Herdman, T; Imwong, M; Lee, SJ; Lim, P; Lindegardh, N; Lwin, KM; Nosten, F; Phyo, AP; Ringwald, P; Silamut, K; Singhasivanon, P; Socheat, D; Tarning, J; White, NJ; Yeung, S; Yi, P | 1 |
| Dokomajilar, C; Greenhouse, B; Ouédraogo, JB; Rosenthal, PJ; Rouamba, N; Séré, YY; Somé, AF; Zongo, I | 1 |
| Awab, GR; Day, NP; Dondorp, AM; Imwong, M; Kaker, F; Lee, SJ; Pukrittayakamee, S; Singhasivanon, P; White, NJ; Woodrow, CJ | 1 |
| Ashley, EA; Lindegardh, N; Lwin, KM; Nosten, F; Phyo, AP; Price, RN; Russell, B; Singhasivanon, P; Sriprawat, K; White, NJ | 1 |
| Ashley, E; Aye, KZ; Barends, M; Htet, L; Kyaw, MK; Lindegardh, N; Lwin, S; Phe, O; Singtoroj, T; Smithuis, F; Stepniewska, K; White, NJ | 1 |
| Barends, M; Keola, S; Khanthavong, M; Lindegårdh, N; Mayxay, M; Newton, PN; Phetsouvanh, R; Phompida, S; Pongvongsa, T; Stepniewska, K; Thongpraseuth, V; White, NJ | 1 |
| Ashley, EA; La, Y; Lindegardh, N; McGready, R; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ | 1 |
| Ashley, EA; Brockman, A; Chan, S; Goubert, L; Janssens, B; Nong, S; Socheat, D; Uong, S; Van Damme, W; van Herp, M | 1 |
| Anstey, NM; Ebsworth, EP; Kenangalem, E; Laihad, F; Maristela, R; Price, RN; Ratcliff, A; Siswantoro, H; Tjitra, E; Wuwung, RM | 1 |
| Ding, Y; Qi, Z; Xu, C | 1 |
| Karbwang, J; Na-Bangchang, K; Palacios, PA; Saengtertsilapachai, S; Ubalee, R; Wernsdorfer, WH | 1 |
1 review(s) available for artenimol and Recrudescence
| Article | Year |
|---|---|
The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Quinolines; Recurrence; Risk; Treatment Outcome | 2019 |
21 trial(s) available for artenimol and Recrudescence
| Article | Year |
|---|---|
Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine.
Topics: Administration, Intravenous; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Malaria, Falciparum; Male; Osmolar Concentration; Plasmodium falciparum; Quinine; Quinolines; Recurrence; Treatment Outcome; Uganda | 2019 |
The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Asymptomatic Infections; Female; Humans; Laos; Malaria, Vivax; Male; Mass Drug Administration; Plasmodium vivax; Polymerase Chain Reaction; Primaquine; Quinolines; Recurrence; Time Factors; Young Adult | 2020 |
Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Cambodia; Child; Female; Humans; Malaria, Falciparum; Malaria, Vivax; Male; Mass Drug Administration; Myanmar; Prevalence; Primaquine; Quinolines; Recurrence; Treatment Outcome; Vietnam; Young Adult | 2020 |
Artemisinin-based combination therapy in pregnant women in Zambia: efficacy, safety and risk of recurrent malaria.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Drug Combinations; Ethanolamines; Female; Fluorenes; Humans; Malaria; Mefloquine; Pregnancy; Quinolines; Recurrence; Risk; Treatment Outcome; Young Adult; Zambia | 2017 |
Comparison of Two Genotyping Methods for Distinguishing Recrudescence from Reinfection in Antimalarial Drug Efficacy/Effectiveness Trials.
Topics: Antigens, Protozoan; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Cluster Analysis; Drug Combinations; Female; Gene Expression; Genotype; Genotyping Techniques; Humans; Malaria, Falciparum; Malawi; Male; Merozoite Surface Protein 1; Merozoites; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins; Quinolines; Recurrence; Treatment Outcome | 2018 |
Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschool; Comparative Effectiveness Research; Drug Combinations; Drug Resistance; Female; Genotype; Humans; Infant; Malaria, Falciparum; Male; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Parasitemia; Plasmodium falciparum; Protozoan Proteins; Quinolines; Recurrence; Single-Blind Method; Uganda | 2019 |
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infant; Malaria, Vivax; Male; Middle Aged; Myanmar; Primaquine; Quinolines; Recurrence; Thailand; Young Adult | 2019 |
Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence.
Topics: Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi-Square Distribution; Child; Child, Preschool; DNA, Protozoan; Drug Combinations; Drug Resistance; Ethanolamines; Fluorenes; Humans; Infant; Kenya; Malaria, Falciparum; Parasitemia; Plasmodium falciparum; Polymerase Chain Reaction; Quinolines; Recurrence | 2013 |
Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial.
Topics: Adult; Antimalarials; Artemisinins; Cambodia; Drug Administration Schedule; Drug Resistance, Multiple; Humans; Malaria, Falciparum; Malaria, Vivax; Male; Military Personnel; Models, Biological; Quinolines; Recurrence | 2014 |
Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschool; Cohort Studies; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; HIV Infections; Hospitalization; Humans; Infant; Longitudinal Studies; Malaria, Falciparum; Male; Quinolines; Recurrence; Time Factors; Treatment Outcome; Uganda | 2014 |
Dihydroartemisinin-piperaquine failure in Cambodia.
Topics: Adult; Antimalarials; Artemisinins; Cambodia; Drug Combinations; Humans; Malaria, Falciparum; Quinolines; Recurrence; Treatment Failure | 2014 |
A trial of combination antimalarial therapies in children from Papua New Guinea.
Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Child, Preschool; Chloroquine; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Infant; Kaplan-Meier Estimate; Lumefantrine; Malaria, Falciparum; Malaria, Vivax; Male; Proportional Hazards Models; Pyrimethamine; Quinolines; Recurrence; Sulfadoxine | 2008 |
Artemisinin resistance in Plasmodium falciparum malaria.
Topics: Administration, Oral; Adolescent; Adult; Animals; Antimalarials; Artemisinins; Artesunate; Drug Resistance; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypoxanthine; Inhibitory Concentration 50; Malaria, Falciparum; Mefloquine; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Genetic; Recurrence; Young Adult | 2009 |
Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.
Topics: Adolescent; Afghanistan; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infant; Malaria, Vivax; Male; Multivariate Analysis; Plasmodium vivax; Prospective Studies; Quinolines; Recurrence; Treatment Outcome | 2010 |
Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Female; Humans; Infant; Malaria, Vivax; Male; Middle Aged; Parasitic Sensitivity Tests; Plasmodium vivax; Quinolines; Recurrence; Risk Factors; Treatment Outcome; Young Adult | 2011 |
Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison.
Topics: Adolescent; Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Malaria, Falciparum; Male; Mefloquine; Myanmar; Plasmodium falciparum; Quinolines; Recurrence; Sesquiterpenes; Treatment Outcome | 2006 |
An open, randomized comparison of artesunate plus mefloquine vs. dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in the Lao People's Democratic Republic (Laos).
Topics: Administration, Oral; Adolescent; Adult; Antimalarials; Artemisinins; Artesunate; Child; Drug Therapy, Combination; Female; Humans; Laos; Malaria, Falciparum; Male; Mefloquine; Parasitemia; Quinolines; Recurrence; Sesquiterpenes; Treatment Failure; Treatment Outcome | 2006 |
The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.
Topics: Adolescent; Adult; Antimalarials; Area Under Curve; Artemether; Artemisinins; Drug Administration Schedule; Ethanolamines; Female; Fluorenes; Follow-Up Studies; Half-Life; Humans; Lumefantrine; Malaria, Falciparum; Male; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Recurrence; Remission Induction; Sesquiterpenes; Tablets; Thailand | 2006 |
A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia.
Topics: Adolescent; Adult; Aged; Anemia; Antimalarials; Artemisinins; Artesunate; Cambodia; Child; Child, Preschool; Drug Therapy, Combination; Female; Genome, Protozoan; Humans; Infant; Malaria, Falciparum; Malaria, Vivax; Male; Mefloquine; Middle Aged; Quinolines; Recurrence; Sesquiterpenes; Treatment Outcome | 2007 |
Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison.
Topics: Adolescent; Adult; Anemia; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, Preschool; Diarrhea; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple; Ethanolamines; Female; Fluorenes; Humans; Indonesia; Infant; Malaria, Falciparum; Malaria, Vivax; Male; Middle Aged; Prospective Studies; Quinolines; Recurrence; Sesquiterpenes; Treatment Outcome; Urticaria; Vomiting | 2007 |
Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria.
Topics: Acute Disease; Adolescent; Adult; Antimalarials; Artemisinins; Biological Availability; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Humans; Malaria, Falciparum; Male; Mefloquine; Recurrence; Sesquiterpenes; Tablets; Thailand; Therapeutic Equivalency; Time Factors | 2000 |
9 other study(ies) available for artenimol and Recrudescence
| Article | Year |
|---|---|
Prevalence of CYP2D6 Genotypes and Predicted Phenotypes in a Cohort of Cambodians at High Risk for Infections with
Topics: Antimalarials; Artemisinins; Asian People; Cambodia; Cytochrome P-450 CYP2D6; Drug Therapy, Combination; Endemic Diseases; Gene Frequency; Genotype; Humans; Malaria, Vivax; Pharmacogenomic Variants; Phenotype; Plasmodium vivax; Polymorphism, Genetic; Primaquine; Quinolines; Recurrence; Treatment Failure | 2020 |
Dihydroartemisinin ameliorates psoriatic skin inflammation and its relapse by diminishing CD8
Topics: Animals; Artemisinins; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Imiquimod; Immunologic Memory; Interleukin-15; Interleukin-17; Male; Methotrexate; Mice; Psoriasis; Recurrence; Secondary Prevention; Skin; Skin Transplantation; Transplantation Chimera | 2020 |
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; Humans; Indonesia; Infant; Malaria, Vivax; Male; Middle Aged; Primaquine; Quinolines; Recurrence; Retrospective Studies; Young Adult | 2017 |
Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model.
Topics: Animals; Antimalarials; Artemisinins; Disease Models, Animal; Drug Combinations; Malaria; Mice; Parasite Load; Parasitic Sensitivity Tests; Plasmodium berghei; Quinolines; Recurrence | 2014 |
An Economic Evaluation of the Posttreatment Prophylactic Effect of Dihydroartemisinin-Piperaquine Versus Artemether-Lumefantrine for First-Line Treatment of Plasmodium falciparum Malaria Across Different Transmission Settings in Africa.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Combinations; Ethanolamines; Fluorenes; Humans; Malaria, Falciparum; Markov Chains; Models, Biological; Models, Economic; Plasmodium falciparum; Quinolines; Recurrence | 2015 |
[Multiple and successive treatment failures in a patient infected by Plasmodium falciparum in Cambodia and treated by dihydroartemisinin-piperaquine].
Topics: Antimalarials; Artemisinins; Cambodia; Drug Therapy, Combination; Humans; Malaria, Falciparum; Male; Middle Aged; Plasmodium falciparum; Quinolines; Recurrence; Treatment Failure | 2016 |
Efficacy of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015.
Topics: Amodiaquine; Angola; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, Preschool; Drug Combinations; Ethanolamines; Female; Fluorenes; Humans; Infant; Malaria, Falciparum; Male; Quinolines; Recurrence; Treatment Failure | 2017 |
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Burkina Faso; Drug Combinations; Drug Resistance, Bacterial; Ethanolamines; Fluorenes; Genotype; Humans; Infant; Lumefantrine; Malaria, Falciparum; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins; Pyrimethamine; Quinolines; Randomized Controlled Trials as Topic; Recurrence; Sulfadoxine | 2010 |
[Efficacy of dihydroartemisinin in treatment of 37 malaria cases].
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Female; Humans; Malaria, Falciparum; Malaria, Vivax; Male; Middle Aged; Recurrence; Sesquiterpenes | 1997 |